Genentech said the phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death compared to chemotherapy alone in the initial treatment of advanced non-squamous non-small cell lung cancer.
The American Cancer Society’s 2026 annual statistics report trumpets a symbolic milestone for oncology—for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed between 2015 and 2021 in the U.S.
